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Abstract 
Over the last several decades, antibacterial drug use has become widespread with their misuse being an ever‑
increasing phenomenon. Consequently, antibacterial drugs have become less effective or even ineffective, resulting 
in a global health security emergency. The prevalence of multidrug‑resistant organisms (MDROs) varies widely among 
regions and countries. The primary aim of antibiotic stewardship programs is to supervise the three most influential 
factors contributing to the development and transmission of MDROs, namely: (1) appropriate antibiotic prescribing; 
(2) early detection and prevention of cross‑colonization of MDROs; and (3) elimination of reservoirs. In the future, it is 
expected that a number of countries will experience a rise in MDROs. These infections will be associated with a high 
consumption of healthcare resources manifested by a prolonged hospital stay and high mortality. As a counteractive 
strategy, minimization of broad‑spectrum antibiotic use and prompt antibiotic administration will aid in reduction 
of antibiotic resistance. Innovative management approaches include development and implementation of rapid 
diagnostic tests that will help in both shortening the duration of therapy and allowing early targeted therapy. The 
institution of more accessible therapeutic drug monitoring will help to optimize drug administration and support a 
patient‑specific approach. Areas where further research is required are investigation into the heterogeneity of critically 
ill patients and the need for new antibacterial drug development.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
International health organizations, including the Euro-
pean Centre for Disease Prevention and Control (ECDC) 
and the Centers for Disease Control and Prevention 
(CDC), have used terms such as “crisis,” “catastrophic 
consequences” and “nightmare scenario” to highlight 
the rapid emergence and spread of antibiotic resistance 
[1–4]. The World Health Organization (WHO) has iden-
tified antimicrobial resistance as one of the most impor-
tant problems for human health with significant adverse 
impacts on clinical outcomes and higher costs due to 
consumption of healthcare resources [5].
Epidemiology of highly resistant bacteria
A number of studies have been performed to assess the 
burden of infection in critical illness. The Intensive Care 
Over Nations (ICON) audit showed that more than 
one-third of the patients develop an infection during 
their intensive care unit (ICU) stay [6]. The Extended 
Prevalence of Infection in Intensive Care (EPIC) II study 
showed that 51  % of patients were considered to be 
infected while in ICU. The infection was of respiratory 
origin in 64 % of cases. S aureus (20.5 %) was the most 
frequent organism isolated, despite the overall predomi-
nance of Gram-negative organisms as a group: 62.2 % (E. 
coli, Enterobacter spp., Klebsiella spp., Pseudomonas spp. 
and Acinetobacter spp.) [7].
Antibiotic resistance is a serious problem in all parts of 
the world including Asia–Pacific, Latin America, Mid-
dle East, Europe and North America regions. A particu-
lar concern is the misuse or overuse of antibiotics, which 
has lead to the development of resistant or super-resist-
ant bacterial strains. Two regions of particular concern, 
with existing high levels of antimicrobial resistance, are 
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South-East Asia and the Middle East where antibiot-
ics can be easily bought over the counter [8, 9]. Findings 
from a cross-sectional study from Saudi Arabia showed 
that antibiotics were dispensed without a medical pre-
scription in 244 (77.6  %) of 327 pharmacies analyzed, 
of which 231 (95  %) were dispensed without a patient 
request [10].
In Europe, the European Antimicrobial Resistance Sur-
veillance Network (EARS-Net) has provided European 
reference data on antimicrobial resistance for public 
health purposes since the program began in 1999. Over 
the last 4 years (2011–2014), the proportion of K. pneu-
moniae and E. coli with resistance to fluoroquinolones, 
third-generation cephalosporins, aminoglycosides and 
a combined resistance to all three antibiotic groups has 
increased significantly. Large inter-country variations in 
Acinetobacter spp. resistance exist in Europe with a high 
percentage of resistant isolates being found in southern 
and southeast Europe. Similar patterns are observed with 
methicillin-resistant Staphylococcus aureus (MRSA) with 
resistance levels varying from 0.9 to 56 % depending on 
the country studied [11]. The recent “European Antimi-
crobial Resistance One Health ministerial conference 
2016” highlighted the substantial antimicrobial resistance 
problem in Europe. For several antimicrobial group–bac-
terium combinations, a north-to-south and west-to-east 
gradient is evident in Europe. In general, lower resistance 
percentages are reported by countries in the north and 
higher percentages by countries in the south and east of 
Europe [12].
A group of international experts brought together by 
a joint initiative between the ECDC and the CDC, was 
tasked with creating a standardized international termi-
nology to describe acquired resistance profiles in multid-
rug-resistant organisms [13]. MDROs have been divided 
into three categories depending on their resistance pro-
file: 1. MDROs—non-susceptible to at least 1 agent in 3 
antimicrobial categories; 2. extensively drug-resistant 
(XDR) organisms—non-susceptible to at least 1 agent in 
all but 2 or fewer antimicrobial categories; and 3. pan-
drug-resistant (PDR) organisms—non-susceptible to all 
agents in all antimicrobial categories (Fig. 1).
Over recent years, a new, comprehensive recommenda-
tion on classification of infections caused by Gram-pos-
itive and emerging Gram-negative multidrug-resistant 
pathogens has been launched. E. faecium, S. aureus, K. 
pneumoniae, A. baumannii, P. aeruginosa and Entero-
bacter spp. (ESKAPE) pathogens account for more than 
80 % of infectious episodes in the ICU. As this acronym 
seems to help to highlight the problem of MDROs, some 
authors [14] claim a change to “ESCAPE” is warranted (E. 
faecium, S. aureus, C. difficile, A. baumannii, P. aerugi-
nosa and Enterobacteriaceae spp.) in order to highlight 
the importance of C. difficile and incorporate not only 
Enterobacter spp. but also other Enterobacteriaceaespp. 
(namely, Escherichia coli and Proteus spp.) because of 
the increasing levels of antibiotic resistance (includ-
ing extended-spectrum β-lactamases, carbapenemases 
and aminoglycoside resistance) and decreasing levels 
of fluoroquinolone susceptibility among these organ-
isms. E. coli infections currently account for ~20 % of all 
cases of bacteremia in the UK and Ireland [15] with not 
just high rates of fluoroquinolone and amoxicillin–cla-
vulanic acid (AMC) resistance, but also extended-spec-
trum beta-lactamase (ESBL) mechanisms with a possible 
link between high resistance and community antibiotic 
misuse [16]. In addition, ESBL Enterobacteriaceae spp. 
are responsible for outbreaks irrespective of location. 
Antibiotic selection of ESBL-producing Gram-negative 
pathogens is not just related to the total use of antimi-
crobial agents in hospitals, but also to the particular use 
of the fluoroquinolones and second- and third-genera-
tion cephalosporins [16]. P. aeruginosa has an extensive 
capability to become resistant to all type of antibiotics, 
create biofilms and demonstrate a high level of intrinsic 
resistance. These characteristics are caused by produc-
tion of ESBL, overexpression of AmpC beta-lactamases 
and other drug-resistant mechanisms such as production 
of metallo-β-lactamases (MBLs) [17]. Acinetobacter spp., 
similar to P. aeruginosa, have an array of mechanisms by 
which they develop and horizontally transfer resistance. 
The most important of these is the production of beta-
lactamases and aminoglycoside-modifying enzymes [18].
As a result of misuse of antibiotics, different pathogens 
are becoming increasingly resistant. The lack of regula-
tory policies regarding antibiotic prescription makes 
them easily accessible and cheap, which promotes over-
use [19]. Gram-negative bacilli are often resistant to mul-
tiple antimicrobials. It is important to mention the newly 
Fig. 1 Multidrug‑resistant organisms (MDR) have been divided into 
three categories depending on their resistance profile: 1. MDR—
non‑susceptible to at least 1 agent in 3 antimicrobial categories; 2. 
extensively drug‑resistant (XDR)—non‑susceptible to at least 1 agent 
in all but 2 or fewer antimicrobial categories and 3. pan‑drug‑resistant 
(PDR)—non‑susceptible to all agents in all antimicrobial categories
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emergence of the first plasmid-mediated polymyxin 
resistance mechanism, MCR-1, in Enterobacteriaceae in 
China [20]. This is especially worrisome because plas-
mid-mediated resistance can spread in an explosive man-
ner and de-activate polymyxins, which are one of our 
last antibiotic options. On the other hand, carbapenems 
are another important last-line group of antibiotics for 
infections involving multidrug-resistant Gram-negative 
Enterobacteriaceae spp. The most important mecha-
nism of carbapenem resistance in this group is the pro-
duction of carbapenemases, although resistance can also 
result from the synergistic activity between AmpC-type 
and extended-spectrum beta-lactamases combined with 
decreased outer membrane permeability. Three major 
molecular classes of carbapenemases are recognized: 
A, B and D (Fig.  2). Although carbapenem resistance 
remains at relatively low levels in northern Europe, it 
does constitute a serious threat worldwide as a conse-
quence of acquisition of carbapenemase genes with a 
higher prevalence in southern Europe and Asia. In South 
America, carbapenem-resistant P. aeruginosa and A. bau-
mannii could be as high as 56 and 35 %, respectively [21]. 
Outbreaks of class A carbapenemases particularly plas-
mid encoded (K. pneumoniae carbapenemases [KPC]) 
producers also have been reported in several countries 
(Greece, Israel, China, Brazil, Argentina and USA) [22]. 
Some authors have proposed two concomitant epidemics 
of carbapenemase producers worldwide [23]: (1) commu-
nity-acquired infections with carbapenemase-producing 
E. coli (New Delhi metallo-β-lactamase-1) (NDM-1 and 
OXA-48 types) and (2) nosocomial carbapenemase pro-
ducers in K. pneumoniae of all types (KPC, IMP, VIM, 
NDM and OXA-48).
There is an urgent need for development of new agents 
with activity against MDROs. The Infectious Diseases 
Society of America (IDSA) supported a program, so-
called Bad Bugs, Need Drugs; 10 × ‘20 Initiative, with the 
aim of developing ten new systemic antibacterial drugs 
by 2020 [24]. In Europe, a recent report from the Econ-
omist Jim O’Neill in the UK expressed concern that the 
global financial cost of no action would be the loss of 10 
million lives a year by 2050 and £69  tn ($100  tn) a year 
[25]. Infections by MDROs were associated with worse 
clinical outcomes compared with their susceptible coun-
terparts [26]. While higher mortality associated with 
MDROs may be related to the virulence of the pathogen 
and a weak (comorbidity, age, etc.) or severely ill host 
(organ failure status, etc.) [27, 28], it is also important to 
highlight that delays in effective antimicrobial adminis-
tration are also associated with high mortality [29].
Risk scoring/risk factors
There have been multiple attempts to identify patients 
at risk of MDROs with the implementation of risk scor-
ing systems to initiate appropriate targeted antibiotic 
therapy. Unfortunately, the value of these scores is lim-
ited [30]. Most of the risk factors are shared among dif-
ferent MDRO species, and the same type of organism 
with various degrees of resistance might have distinct 
epidemiological characteristics. Martin-Loeches et  al. 
[31] confirmed in a multicenter study that patients with-
out risk factors listed in the 2005 ATS/IDSA guidelines 
admitted to ICU with hospital-acquired pneumonia 
(HAP) and/or ventilator-associated pneumonia (VAP) 
had a high prevalence of MDROs (50.7 %) confirming the 
difficulty of predicting MDROs based on risk stratifica-
tion. Most clinicians use certain risk profiles (complex 
ICU stay, recent prior hospitalization or long-term care 
facility habitant, recent exposure to antimicrobials, etc.) 
to assess the need for broad-spectrum antibiotic therapy. 
This approach certainly improves adequate initial antibi-
otic choice, but again shares the same concerns with risk 
scores being non-specific and broad. If broad-spectrum 
antibiotics, based on risk scores or risk stratification, 
are prescribed, strict antibiotic stewardship programs 
should be also applied. This strategy, mainly based on de-
escalation policies, will ultimately promote higher rates 
of appropriate antibiotic use. The recent launch of the 
IDSA/ATS guidelines for HAP/VAP will certainly help 
how to consider antibiotic treatment regarding the afore-
mentioned concerns [32]. Strengths from these recently 
published guidelines are that VAP by MDR pathogens 
is significantly simplified and for the first time clinical 
parameters are included, namely septic shock on appear-
ance of VAP and acute respiratory distress syndrome 
(ARDS) preceding VAP diagnosis.
Fig. 2 Types of carbapenemases. KPC Klebsiella pneumoniae car‑
bapenemase, SME Serratia marcescens enzyme, MNC not metallo‑
carbapenemase, IMI imipenem‑hydrolyzing β‑lactamase, GES 
Guiana extended spectrum, IMI imipenem‑hydrolyzing β‑lactamase, 
VIM Verona integron‑encoded MBL, NDM‑1 New Delhi metallo‑β‑
lactamase
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Another approach is to perform regular surveillance. 
Based on previous observational studies MDROs colo-
nization may precede bacteraemia in the ICU [33]. This 
early identification of MDROs—even before clinical 
infection—can guide the clinician toward appropri-
ate empiric treatment. Brusselaers et al. [34] in a recent 
meta-analysis of tracheal aspirate surveillance concluded 
that such an approach has a high negative predictive 
value, i.e., if a recent surveillance culture does not con-
tain MDROs, the newly symptomatic VAP is unlikely to 
be caused by MDROs (likelihood <10  %). However, the 
presence of MDROs only had a moderate positive predic-
tive value with an overall 75 % sensitivity.
Rapid methods to diagnose multidrug resistance
One of the key aspects of avoiding the spread of resist-
ant strains is early detection with the use rapid diag-
nostic tests. The methods currently used in hospitals 
for microbial detection tend to be labor-intensive, con-
sume human resources and take more than a day to yield 
results. Newly developed rapid microbial detection tests, 
which biopharmaceutical industries have been slow to 
embrace, are precise, sensitive and generate results faster 
when compared with traditional culture-plate methods. 
There has been growing experience with rapid diagnos-
tic techniques within the last decade, especially with 
MRSA. Harbarth et al. [35] using quick, multiplex immu-
nocapture-coupled PCR (qMRSA) were able to decrease 
median time to notification from four days to one day 
which can help to identify previously unknown MRSA 
carriers rapidly. Experience with Gram-negative isolates 
such as carbapenemase-producing organisms (CROs), 
including the Enterobacteriaceae spp., is also evolving. 
Detection of patients carrying carbapenemase-producing 
microorganisms can significantly impact on infection 
control. Recently, Tato et al. assessed the performance of 
the Cepheid Xpert Carba-R assay (designed for the rapid 
detection and differentiation of the blaKPC, blaNDM, 
blaVIM, blaOXA-48 and blaIMP-1 genes) and found 
that sensitivity, specificity, positive and negative predic-
tive values compared to reference culture and sequenc-
ing results were above 95  %. Worryingly, in addition to 
CROs, there has been an increase in reports of Entero-
bacteriaceae spp. resistant to polymyxins. Since conven-
tional methods for detection of colistin-resistant isolates 
such as microdilution are time-consuming and methods 
like disk diffusion and the E-test are not reliable, Nord-
mann et al. [36] evaluated a new test: a chromogenic agar, 
shortening the results by 16 h compared to the reference 
broth dilution method, with a sensitivity and specificity 
of 99.3 and 95.4 %, respectively, compared to the stand-
ard microdilution method.
Shortening the turn-around time of positive blood cul-
ture identification and susceptibility results is essential to 
optimize antimicrobial treatment in patients with severe 
infections. One of the most widely used technologies 
nowadays that actually has revolutionized the process of 
care in microbiology laboratories is the matrix-assisted 
laser desorption ionization/time-of-flight mass spec-
trometry (MALDI-TOF MS) [37]. The introduction of 
mass spectrometry through MALDI-TOF in the diag-
nosis of bacteraemia and fungemia has represented a 
revolution due to the rapidity and reliability of the results 
that it can offer to microbiology services and laboratories 
through analysis of the mass spectrum of the bacterial 
protein directly from positive blood culture bottles [38]. 
Management of patients with bacteraemia has been opti-
mized with the introduction of this methodology due to 
the rapid information.
Rapid diagnostic tests implemented in the current 
clinical practice should also consider an adequate work-
flow of information within a multidisciplinary working 
group approach that can process quickly and correctly 
the results from the microbiology laboratory to the bed-
side of the patient. An adequate process of care perfor-
mance of rapid diagnostic tests such as MALDI-TOF will 
improve the quality of care, with the reduction of antibi-
otic expenditure and hospital stay and helping to infec-
tion control with the implementation of adequate and 
timing transmission-based precautions [39].
The basis for all infection control measures is the accu-
rate and timely laboratory identification of MDROs. 
This will also deliver important information for regional 
and national containment strategies and hospitals. The 
implementation of rapid tests and the development of 
microbiology laboratory reference services is an urgent 
requirement.
Antibiotic stewardship (AMS) and infection control 
strategies
Antimicrobial stewardship (AMS) programs aim to pro-
vide assistance with optimal choice, dosage, pharmacoki-
netic–pharmacodynamic (PK/PD) characteristics and 
duration of antibiotics in order to reduce costs, adverse 
events and the development of resistance [40]. Even 
though the IDSA has published guidelines [41] about 
AMS programs, the ideal care bundle has yet to be iden-
tified as published articles vary greatly in their findings. A 
systematic review by Kaki et al. [42] assessing 24 mainly 
uncontrolled, before and after studies published in 2011 
showed that marked heterogeneity exists with respect to 
interventions evaluated and no mortality benefit could 
be identified. Nevertheless, AMS was associated with 
an overall clinical benefit as evidenced by a reduction in 
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antibiotic consumption, costs and antibiotic pressure that 
subsequently results in a decrease in resistance rates [42].
These measures are only effective if all stakeholders, 
supported by the relevant authorities, accept imple-
mentation and incorporate audits and feedback mecha-
nisms. A recent example of such an initiative is the “Zero 
Resistance” program developed by The Spanish Society 
of Intensive Care Medicine and Coronary Care Units 
(SEMICYUC). The main objective of the “Zero Resist-
ance” project is reduction in the cumulative incidence 
of patients with ICU-acquired MDR infections by 20  % 
with a bundle of 10 recommendations. The primary aim 
of the antibiotic program is to supervise the three most 
influential contributing factors to the development and 
transmission of MDROs, namely: (1) adequate prescrip-
tion of antibiotics; (2) early detection and prevention of 
cross-colonization of MDR; and (3) elimination of reser-
voirs [43]. Results of this ambitious project will shed light 
on AMS programs in the near future.
De-escalation is defined as an AMS strategy of reduc-
ing the number of antibiotics or using narrower/tar-
geted spectrum drugs. De-escalation has been found 
to be safe and associated with less antibiotic usage and 
shorter duration of therapy in observational stud-
ies. Theoretically, this will translate into a reduction of 
MDROs; nonetheless, it has yet to be clearly proven [44]. 
Two studies have recently been published looking at 
de-escalation in patients with severe sepsis. Leone et al. 
[45] conducted a multicenter non-blinded randomized 
non-inferiority trial of patients with severe sepsis and 
Garnacho-Montero et  al. [46] a prospective observa-
tional study enrolling patients admitted to the ICU with 
severe sepsis or septic shock. While Leone et  al. [45] 
found that de-escalation was inferior to continuation of 
the initial antibiotic therapy (length of stay as the primary 
outcome parameter), the study had important limita-
tions (small numbers of patients and unbalanced groups 
at baseline; patients were younger and had lower disease 
severity). Garnacho-Montero et  al. [46] demonstrated a 
protective effect of de-escalation in terms of mortality. In 
an observational, single-center study, Montravers et  al. 
[47] prospectively analyzed the characteristics and out-
comes of anti-infective de-escalation during healthcare-
associated intra-abdominal infections and found that 
the presence of non-fermenting Gram-negative bacilli 
(NFGNB) and MDROs limited the implementation of a 
de-escalation program. De-escalation is a feasible option 
in patients with polymicrobial infections such as health-
care-associated intra-abdominal infections, but MDROs 
and NFGNB limit its implementation. Recently, De Bus 
[48] et  al. analyzed the effect of de-escalation in 478 
anti-pseudomonal antibiotic prescriptions and could not 
find lower rates of resistant organisms after exposure to 
anti-pseudomonal beta-lactam antibiotics. Interestingly, 
Carlier et  al. [49] conducted a simulation study show-
ing that the probability of achieving a PK/PD target was 
lower in the narrower-spectrum antibiotic group (amoxi-
cillin–clavulanic acid, cefuroxime, flucloxacillin, cefazo-
lin and cefepime) using conventional dosing as compared 
to broad-spectrum antibiotics like meropenem and 
piperacillin/tazobactam.
Combination antimicrobial therapy exploits the syner-
gistic effect of some antibiotic groupings in addition to 
broadening the spectrum of activity against a suspected 
pathogen to ensure adequate coverage. The synergistic 
effect of combination therapy has been shown to be ben-
eficial in vivo in invasive pneumococcal disease and toxic 
shock syndrome. Randomized controlled trials (RCTs), 
on the other hand, have failed to demonstrate a mortality 
benefit with B-lactam and aminoglycoside combinations, 
but renal damage was more frequent [50]. Treatment of 
infections caused by CROs using a combination of two or 
three active drugs has consistently been associated with 
improved outcomes, with carbapenems being included 
in the combination when the minimal inhibitory concen-
tration (MIC) of the pathogen against meropenem does 
not exceed 8  mg/L [51, 52]. However, a survival benefit 
when using combination treatment for infections caused 
by multidrug-resistant Gram-negative bacteria is ques-
tionable [53–55]. As almost all these data originate from 
observational studies, the need for RCTs is clear.
There is an on-going debate about pharmacokinetic and 
pharmacodynamic (PK/PD) optimization. On the one 
hand, the critically ill patient has a higher than normal 
volume of distribution, impaired renal and hepatic clear-
ance, altered plasma protein content and they also tend 
to be elderly with significant comorbidities. On the other 
hand, there is growing evidence that in selected patient 
populations renal clearance is actually augmented, which 
can lead to inadequate plasma concentrations for some of 
the important antibiotic groups like carbapenems, beta-
lactams and cephalosporins. Yang et al. [56] published a 
systemic review showing that the extended or continu-
ous infusion of beta-lactams (piperacillin/tazobactam) 
strategy was associated with a higher clinical cure rate 
and lower mortality than the conventional intermittent 
approach. In patients with multiorgan failure and renal 
replacement therapy, residual diuresis, type of membrane 
and body weight should be considered for beta-lactam 
dose titration [57, 58]. Another frequently used drug 
class to treat MDROs are the aminoglycosides. Recent 
studies have highlighted the need for dose adjustment 
in critically ill patients. De Montmollin et al. [59] found 
that one-third of the patients in ICU had an amikacin 
Cmax < 60 mg/L with the recommended dose of 15 mg/
kg of total body weight. This suggests the need for dose 
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optimization based on creatinine clearance, total body 
weight and positive 24-h fluid balance in order to reach 
adequate therapeutic targets [60, 61]. Until drug assays 
are routinely available, a personalized approach to dos-
ing should be considered for each patient based on local 
AMS.
Because of the increasing prevalence of Gram-negative 
MDROs worldwide, previously discarded antibiotics are 
being re-evaluated. Recent data suggest that the current 
dosage regimens of colistin are suboptimal in many criti-
cally ill patients [62]. To optimize the plasma level the 
administration of a loading dose has been proposed [63]. 
It has also recently been shown [64] that the dose of other 
“rescue” drugs such as fosfomycin should be increased 
for critically ill patients.
Infection control teams play a definitive role in antibi-
otic AMS programs by assisting with prompt detection 
of MDROs and promoting compliance with standard 
and transmission-based precautions. They also facilitate 
the use of other infection prevention strategies, such as 
implementing care bundles to prevent hospital-acquired 
infections, ensuring hand hygiene compliance and edu-
cating not only staff and patients, but also visitors about 
infection prevention topics. Therefore, infection con-
trol teams play a crucial part in AMS. Infection control 
and epidemiology professionals launched the concept of 
“synergy” to highlight the joint effort of infection preven-
tion and AMS [65]. This initiative has three key aims: (1) 
minimize nosocomial infections, (2) decrease the use of 
additional antibiotics and (3) reduce MDROs.
Current and new treatment options
Two major organizations, the IDSA and ECDC, have 
analyzed the repertoire of drugs in the antibiotic R&D 
pipeline, and there are very few offering significant ben-
efits over existing therapies (Table 1) [66].
MRSA is a major MDRO in ICU’s around the globe. 
It is frequently treated with vancomycin, linezolid, dap-
tomycin, ceftaroline or tigecycline. Linezolid was found 
to be superior for the treatment of HAP in the ZEPHyR 
trial [67] in terms of cure rate and nephrotoxicity. Dap-
tomycin is a good alternative, but not licensed for pneu-
monia as the drug is inactivated by surfactant [68]. As a 
new alternative for MRSA, the novel tedizolid was found 
to be non-inferior to linezolid in early clinical response 
for an acute bacterial skin and skin structure infections 
(ABSSSI) [69]. Moreover, recent in  vitro studies also 
confirmed activity against all Gram-positive isolates, 
which were inhibited by ≤1 μg/mL tedizolid in samples 
of patients with HAP. Antimicrobial susceptibility testing 
revealed that the MIC90 of tedizolid was 0.5  μg/mL for 
MRSA, which was fourfold lower than that of linezolid 
[70].
Enterococci are Gram-positive facultative anaerobes 
that live as commensals in the gastrointestinal tract, but 
they are not as virulent as S. aureus or S. pneumoniae. 
Donskey et  al. [71] conducted a prospective study and 
found that vancomycin-resistant enterococci (VRE) in 
stool were associated with treatment with anti-anaerobic 
antimicrobials. More recently, an animal study found 
that in contrast to vancomycin, fidaxomicin (a new class 
of narrow spectrum macrocyclic antibiotic drugs) treat-
ment caused minimal disruption of the intestinal flora 
and did not increase the rate of VRE and extended-
spectrum β-lactamase-producing Klebsiella pneumoniae 
(ESBL-Kp) colonization [72]. Limiting the use of such 
agents may help decrease the spread of VRE. Enterococci 
spp. are likely to function as a reservoir of drug resistance 
determinants and can serve as the springboard for the 
spread of these genes to other Gram-positive pathogens 
[73]. It is important to highlight that there is a relatively 
high rate of VRE not susceptible to linezolid observed 
in ICU patients [31]. New agents like dalbavancin, orita-
vancin and telavancin seem promising [74].
Treatment of carbapenem-resistant Enterobacteriaceae 
spp. using monotherapy is often inadequate, and chal-
lenging cases may require the use of highly toxic agents. 
Aminoglycosides, polymyxins, tigecycline, fosfomycin 
and occasionally fluoroquinolones form the backbone 
of treatment. Recently, the US Food and Drug Admin-
istration (FDA) issued a warning regarding the risk of 
increased mortality in patients treated with tigecycline, 
observed in the clinical trials [75]. An observational study 
by Montravers et al. [76] found it can be used safely even 
in severe infections. However, a debate about the poten-
tial benefit of a high dosage regimen (200 mg daily) still 
needs to be resolved. Combination antimicrobial therapy 
has been shown to be superior in terms of cure rate when 
compared to monotherapy in multiple observational 
studies [77]. Emerging treatment options include cef-
tazidime–avibactam. Avibactam is a novel β-lactamase 
inhibitor with activity against class A, class C and some 
class D β-lactamases. It has activity against KPC-type 
carbapenemases and some OXA enzymes; however, it 
has no activity against metallo-β-lactamases (such as 
NDM-1) [78]. Ceftazidime–avibactam was approved by 
the Food and Drug Administration (FDA) in 2015 for 
the treatment of complicated intra-abdominal infec-
tions and complicated UTIs [79]. A newly released fifth-
generation cephalosporin ceftolozane combined with a 
beta-lactamase inhibitor tazobactam has potent activity 
against P. aeruginosa, including various MDR types [80]. 
Another alternative for the treatment of MDR, XDR and 
PDR Pseudomonas ssp. is the use of intra-tracheal anti-
biotics (ITA), consisting mainly of aminoglycosides and 
polymyxins, with encouraging results seen to date. In 
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mechanically ventilated patients, the use of ITA for pre-
vention or treatment of VAP has shown less toxicity as 
compared to systemic formulations [81]. A recent inter-
national survey reported that intra-tracheal antibiotic 
administration is a common therapeutic modality in 
ICUs; however, practice varies widely [82]. Acineto-
bacter spp. similar to P. aeruginosa have ample ways to 
develop and horizontally transfer resistance. Of greatest 
Table 1 Adapted from [66]
Company Product Class/structure Mechanism of action Lead indication
Actelion Ltd. (SIX:ATLN) Cadazolid (179811) Oxazolidinone–quinolone 
hybrid










CG400549 FabI enoyl‑(acyl carrier pro‑
tein) reductase inhibitor
Inhibit fabI Complicated ABSSSI
GlaxoSmithKline plc(LSE:GSK; 
NYSE:GSK)
GSK1322322 Peptide deformylase (PDF) 
inhibitor
Inhibit PDF Bacterial infection
Furiex Pharmaceuticals Inc. 
(NASDAQ:FURX)/Johnson & 
Johnson (NYSE:JNJ)
JNJ‑32729463 (JNJ‑Q2) Fluoroquinolone Inhibit DNA replication ABSSSI, CAP
Nabriva Therapeutics AG/
Forest Laboratories Inc. 
(NYSE:FRX)
BC‑3781 Pleuromutilin Inhibit protein synthesis ABSSSI
Novartis AG (NYSE:NVS) LFF571 Thiopeptide Inhibit protein synthesis CDAD
PolyMedix Inc. (OTCBB:PYMX) Brilacidin (PMX‑30063) Defensin mimetics Membrane lysis ABSSSI
Rib‑X Pharmaceuticals Inc. Radezolid (RX‑1741) Oxazolidinone Inhibit protein synthesis CAP
Tetraphase Pharmaceuticals 
Inc.





Inhibit cell wall synthesis Gram‑positive cSSSI
Wockhardt Ltd. (BSE:532300) WCK 771 Fluoroquinolone Inhibit DNA replication S. aureus 
Wockhardt Ltd. (BSE:532300) WCK 2349 Fluoroquinolone Inhibit DNA replication Gram‑positive cSSSI
Nanotherapeutics Inc. Ramoplanin Lipoglycodepsipeptide Inhibit cell wall production CDAD
2 M BioTech L.P. CBR‑2092 Rifamycin–quinolone hybrid Inhibit DNA replication and 
RNA synthesis
S. aureus





WAP‑8294A2 Depsipeptide Disrupt membrane MRSA
Basilea Pharmaceutica AG 
(SIX:BSLN)
BAL30072 Beta‑lactam (monocyclic) Inhibit cell wall synthesis Gram‑negative
FAB Pharma S.A.S. FAB001 (MUT056399) FabI enoyl‑(acyl carrier pro‑
tein) reductase inhibitor
Inhibit fabI S. aureus
Kalidex Pharmaceuticals Inc. KPI‑10 Fluoroquinolone Inhibit DNA replication Gram‑negative and Gram‑
positive
Kyorin Pharmaceutical Co. 
Ltd. (Tokyo:4569)
KRP‑AM1977X Quinolone Inhibit DNA replication Gram‑positive
MicuRx Pharmaceuticals Inc. MRX‑I Oxazolidinone Inhibit protein synthesis Gram‑positive
Novacta Biosystems Ltd. NVB302 Lantibiotic Inhibit cell wall synthesis CDAD
Rempex Pharmaceuticals Inc. Carbavance (RPX7009/bia‑
penem)
Beta‑lactamase inhibitor 
with boron core (RPX7009); 
beta‑lactam (biapenem)
Inhibit cell wall synthesis Gram‑negative
Shionogi & Co. Ltd.
(Tokyo:4507)/GlaxoS‑
mithKline plc (LSE:GSK; 
NYSE:GSK)
S‑649266 Beta‑lactam Inhibit cell wall synthesis CAP
Tetraphase Pharmaceuticals 
Inc.
TP‑2758 Tetracycline Inhibit protein synthesis cUTI
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significance is the production of beta-lactamases and 
aminoglycoside-modifying enzymes [18]. Combination 
therapy including a polymyxin has commonly been the 
mainstay of treatment for Acinetobacter spp. However, a 
recent paper has highlighted the risk of nephrotoxicity 
when colistin and vancomycin are used in combination 
with no benefit to clinical outcome [83].
More recently, studies have been conducted reveal-
ing the benefits of treatment with “new” combination 
therapies for XDR or PDR organisms. In terms of PDR 
Gram-negative infections, Bulik et  al. [84] found that 
double-carbapenem therapy (ertapenem and dorip-
enem) for carbapenemase-producing K. pneumoniae 
had an enhanced efficacy over either agent alone both 
in  vitro and in  vivo in animal models. Giamarellou 
et  al. [85] found that the use of ertapenem plus dorip-
enem or meropenem resulted in treatment success 
without relapse at follow-up in patients with PDR K. 
pneumoniae.
As the vast majority of the antibiotic treatment is short 
term, many companies struggle to generate profit from 
the sales of anti-infective agents. The majority of prod-
ucts being approved are second-, third- or fourth-genera-
tion antibiotics, meaning they are follow-up compounds, 
without a novel mechanism of action. In addition to 
this, many novel antibiotics have struggled to reach the 
market due to difficulties in demonstrating efficacy or 
unacceptable side effects. Furthermore, for licensing pur-
poses, new antibacterials must demonstrate non-inferi-
ority against already marketed drugs. Finally, healthcare 
authorities are frequently reluctant to pay the high costs 
associated with clinical trials, hindering the development 
of novel antimicrobial agents.
As a result of the declining effectiveness of existing 
antibiotics and the steady decrease in new antibiotic 
development, alternative approaches to antibiotic ther-
apy are appearing including immunotherapy and the use 
of bacteriophages. Immunotherapy initiated at the outset 
of an antibiotic course has the potential to result in ben-
eficial effects; however, use is frequently limited by a nar-
row spectrum of action against specific target antigens. 
Another attractive approach to address the critical need 
for new antibiotics is the engineering of various compo-
nents of the immune response such as monoclonal anti-
bodies. For instance, a randomized, placebo-controlled 
phase I study found that IC43 (recombinant outer mem-
brane protein-based vaccine against P. aeruginosa) could 
induce an antibody response in healthy volunteers [86]. 
Phase II and III studies are being conducted in mechani-
cally ventilated patients (ClinicalTrials.gov Identifier: 
NCT01563263). Another cutting edge approach is the 
use of bacteriophages or phages. These are bacterial 
viruses that invade bacterial cells, disrupt metabolism, 
cause bacteriolysis and are highly specific and effective 
[87].
Future prospects
Infections with MDROs are already a threat in a number 
of countries. It is expected that in others with existing low 
level of MDROs, the number of infections due to MDR, 
XDR and even PDR organisms will rise. These infections 
are associated with an increased consumption of health-
care resources manifested by a prolonged hospital stay 
and an augmented mortality. In order to reduce antibiotic 
resistance rates, a strategy minimizing the use of broad-
spectrum antibiotics and ensuring prompt antibiotic 
administration should be adopted. The development of 
rapid diagnostic tests will help by both shortening dura-
tion of therapy and allowing prompt-targeted therapy. 
The implementation of more accessible therapeutic drug 
monitoring will help to optimize drug administration and 
enable a more personalized approach to treatment. Some 
points require further investigation in clinical trials, such 
as the heterogeneity of patients admitted to ICU and the 
need for new drug development.
Since late 1980s, no new class of antibiotics has been 
discovered that is available for treatment of systemic bac-
terial infections. This discovery void is still impacting the 
therapeutic options to treat infections caused by multi-
drug- or extensively drug-resistant bacteria. Recent find-
ings regarding existing antibiotics combinations should 
also be mentioned. Combination therapy regimens with 
daptomycin with either oxacillin (enhancing in vivo effi-
cacy to daptomycin monotherapy due to a daptomycin–
oxacillin seesaw phenomenon in vitro) [88] or β-lactams 
[89] have been showed to enhance daptomycin efficacy 
against daptomycin-resistant strains. These examples just 
want to illustrate a “think outside of the box” model for 
existing drug combination for new research in the future. 
Certainly, it would need a deep remodel of the current 
drug regulation for new antibacterials and to adequately 
stimulate investment by the industry for new antimi-
crobial developments and ultimately to non-antibiotic 
approaches.
In summary, a steady resistance increase particularly 
to Gram-negatives, rising minimum inhibitory concen-
tration in methicillin-resistant Staphylococcus aureus 
and the spread of multiresistant strains of pathogens in 
patients without classic risk factors in the ICU are key 
areas to delineate in future studies. Guidelines and rec-
ommendations will need to incorporate the ecology of 
the hospital setting and the severity of patient illness to 
provide a personalized patient approach to antimicrobial 
treatment in the future.
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